Cat Vaccine Market Report 2026

The cat vaccine market size has grown strongly in recent years. It will grow from $1.26 billion in 2025 to $1.38 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising incidence of feline infectious diseases, limited availability of advanced vaccines, growth of pet ownership, expansion of veterinary clinics, government vaccination initiatives.

The cat vaccine market size is expected to see strong growth in the next few years. It will grow to $1.93 billion in 2030 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to technological advancements in vaccine development, increasing demand for recombinant and dna vaccines, rising awareness of preventive healthcare in pets, expansion of online veterinary services, integration of ai and data analytics in disease monitoring. Major trends in the forecast period include increased adoption of core vaccination programs, growth of recombinant and dna vaccines, expansion of veterinary healthcare services, rising awareness of pet health and disease prevention, integration of telemedicine and remote monitoring in veterinary care.

The rise in zoonotic diseases is expected to drive the growth of the cat vaccine market. Zoonotic diseases are infections that can transfer from animals to humans through various pathogens such as bacteria, viruses, fungi, or parasites. These diseases can be transmitted via direct contact, vectors, or contaminated environments. Common zoonotic diseases include Lyme disease, rabies, toxoplasmosis, salmonellosis, and brucellosis. Factors contributing to the increase in zoonotic diseases include climate change, antibiotic resistance, and wildlife trade. Cat vaccines help manage these diseases by reducing the risk of transmission from cats to humans. For instance, they protect against diseases such as toxoplasmosis and cat scratch fever. By vaccinating cats, the impact of zoonotic diseases on human health is mitigated, supporting public health and creating a healthier environment for both pets and their owners. According to a February 2024 report from the Government of the United Kingdom, England saw 335 confirmed cases of Lyme disease in the fourth quarter of 2023, up from 273 cases in the same period in 2022. This increase underscores the growing demand for cat vaccines driven by rising zoonotic diseases.

Key players in the cat vaccine market are innovating with products such as NOBIVAC NXT vaccines, which use advanced Ribonucleic acid (RNA)-particle technology to boost immune responses and enhance vaccine effectiveness. This technology involves RNA molecules encased in nanoparticles that deliver genetic instructions to cells, prompting them to produce specific proteins that trigger a targeted immune response. For example, in June 2024, MSD Animal Health Inc. launched the NOBIVAC NXT Rabies portfolio, including NOBIVAC NXT Feline-3 Rabies and NOBIVAC NXT Canine-3 Rabies. These vaccines offer robust protection against rabies for cats and dogs without adjuvants or preservatives, improving safety while maintaining efficacy. They stimulate both humoral and cell-mediated immune responses for comprehensive protection against the rabies virus.

In September 2024, Boehringer Ingelheim Group, based in Germany, acquired Saiba Animal Health AG, a Switzerland-based company specializing in cat vaccines. This acquisition aligns with Boehringer Ingelheim's strategy to expand its portfolio and leverage Saiba’s expertise in the field.

Major companies operating in the cat vaccine market are Merck & Co. Inc., Boehringer Ingelheim International GmbH, Zoetis Inc., MSD Animal Health, Elanco Animal Health Incorporated, Ceva Santé Animale, Virbac, HIPRA Corporation, Bioveta AS, Biogénesis Bagó SA, Torigen Pharmaceuticals Inc., Vetoquinol SA, Phibro Animal Health Corporation, IDT Biologika GmbH, Vaxxinova BV, Colorado Serum Company, Huvepharma NV, Bimeda Biologicals, CAVAC, Kyoto Biken Laboratories, Avimex Animal Health, Ringpu Biology, Wuhan Keqian Biology, Pulike Biological Engineering, Chengdu Kanghua Biological Products, Yebio, FATRO.

North America was the largest region in the cat vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cat vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cat vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the cat vaccine market by affecting the cost and availability of imported vaccine components, raw materials, and advanced biotechnological equipment. These tariffs have increased production costs, particularly impacting segments like recombinant and DNA vaccines and regions heavily reliant on imports such as North America and Europe. While tariffs pose challenges in terms of cost pressures, they also encourage local manufacturing and innovation, potentially driving the development of cost-efficient vaccines and strengthening regional supply chains.

The cat vaccine market research report is one of a series of new reports that provides cat vaccine market statistics, including cat vaccine industry global market size, regional shares, competitors with a cat vaccine market share, detailed cat vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the cat vaccine industry. This cat vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A cat vaccine is a biological agent designed to safeguard cats from infectious diseases by activating their immune system to identify and combat specific pathogens. These vaccines use weakened or inactivated versions of viruses or bacteria responsible for diseases, which prompts the cat’s immune system to generate antibodies without causing illness.

Ther main categories of cat vaccines are modified or attenuated live vaccines, inactivated vaccines, and others. Modified or attenuated live vaccines involve weakening the pathogen to prevent it from causing illness in cats. These vaccines address various diseases such as feline leukemia, feline panleukopenia, feline respiratory infections, and feline rabies. The available vaccine technologies include attenuated live vaccines, conjugate vaccines, inactivated vaccines, subunit vaccines, toxoid vaccines, DNA vaccines, and recombinant vaccines. They can be administered through different methods, including injections, intranasal, and oral routes. These vaccines are available through various channels, including veterinary clinics, pet stores, and online retailers.

The cat vaccine market consists of sales of the bordetella vaccine, rabies vaccine, and feline immunodeficiency virus (FIV) vaccine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.